Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Ther Pat. 2011 Sep;21(9):1285-92. doi: 10.1517/13543776.2011.604314.

Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitors.

Author information

  • 1National Cancer Institute , Center for Cancer Research, Laboratory of Molecular Pharmacology , National Institutes of Health , Bethesda, MD, 20892 , USA.

Abstract

Inhibitors of topoisomerase I (Top1) that result in stalled Top1 cleavage complexes (Top1cc) are commonly employed against cancer. Combination chemotherapy with DNA repair inhibitors can potentially improve response to these widely used chemotherapeutics. One line of inquiry focuses on inhibitors of tyrosyl-DNA phosphodiesterase 1 (Tdp1), a repair enzyme for Top1cc. Tdp1 catalyzes the hydrolysis of DNA adducts covalently linked to the 3'-phosphate of DNA, including Top1-derived peptides and also 3'-phosphoglycolates. Tdp1 inhibitors should synergize not only with Top1-targeting drugs (camptothecins, indenoisoquinolines), but also with bleomycin, topoisomerase II (Top2) inhibitors (etoposide, doxorubicin) and DNA alkylating agents. Here, we summarize the structure-activity relationship obtained from the reported Tdp1 inhibitors. Better understanding of Top1cc repair in vivo coupled with detailed structural studies on Tdp1-inhibitor interaction will be crucial in guiding the rational design of Tdp1 inhibitors.

PMID:
21843105
[PubMed - indexed for MEDLINE]
PMCID:
PMC3157054
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare Icon for PubMed Central
    Loading ...
    Write to the Help Desk